Guilford
Executive Summary
Fourth quarter revenues from sales of the company's Gliadel wafer glioma therapy are projected to be $1.8 mil. in transfer sales and royalties, $700,000 of which are royalties alone, Guilford CEO Craig Smith, MD, told analysts Jan. 12. The company has plans to continue to build Gliadel sales with two potential new indications and a high dose version of the BCNU-containing polymer implant. Guilford and partner Rhone-Poulenc Rorer are conducting a Phase III trial for Gliadel as a first-line therapy, and a Phase II metastatic brain cancer trial
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth